• 1
    Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 2003; 62 Suppl 2 : ii3742.
  • 2
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, and the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 3
    Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-α antagonists. Drug Saf 2004; 27: 30724.
  • 4
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098104.
  • 5
    Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39: 2959.
  • 6
    CDC. Tuberculosis associated with blocking agents against tumor necrosis factor-α, California, 2002–2003. MMWR Morb Mortal Wkly Rep 2004; 53: 6836.
  • 7
    Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 14369.
  • 8
    Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, on behalf of the BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 21227.
  • 9
    Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 3729.
  • 10
    Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 14855.
  • 11
    CDC. Reported tuberculosis in the United States, 2003. Atlanta: CDC, Department of Health and Human Services; September 2004.
  • 12
    The World Health Organization Web site. URL:
  • 13
    Patientregistret 1987–1996 kvalitet och innehåll. Stockholm: Epidemiologiskt Centrum, Socialstyrelsen; 1998.
  • 14
    Lunde AS, Lundeborg S, Lettenstrom GS, Thygesen L, Huebner J. The person-number systems of Sweden, Norway, Denmark, and Israel. Vital Health Stat 2 1980; 2: 159.
  • 15
    Soderlin MK, Borjesson O, Kautiainen H, Skogh T, Leirisalo-Repo M. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis 2002; 61: 9115.
  • 16
    Feltelius N, Fored M, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, et al. Results from a nationwide post marketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005; 64: 24652.
  • 17
    Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 31518.
  • 18
    Evans SJ. Pharmacovigilance: a science or fielding emergencies? Stat Med 2000; 19: 3199209.
  • 19
    The Swedish Tuberculosis Index. Stockholm: The Swedish Institute for Infectious Disease Control; 2000.
  • 20
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis [abstract]. Arthritis Rheum 1988; 31: 31524.
  • 21
    Baecklund E, Ekbom A, Feltelius N, Iliadou A, Backlin C, Askling J, et al. Disease activity, but not DMARD use, increases the risk for malignant lymphoma in rheumatoid arthritis: a case-control study of 378 RA lymphoma patients. Ann Rheum Dis 2004; 63: Supp l1: 103.